Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.
about
A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutantsHIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanismPurification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitorsStructural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding InhibitorRilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabineImpact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsFitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latencyDrug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integraseImpact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA PolymeraseCharacterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.Biochemical mechanism of HIV-1 resistance to rilpivirine.Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptaseCombination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir.Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitorsBasis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase.The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.Drug resistance in HIV-1.Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication.Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant virusesIdentification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor.Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.2014 Update of the drug resistance mutations in HIV-1Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
P2860
Q27675380-9F7C8FFB-12B8-4F6D-9280-638927A5363DQ27676835-DCB90C8B-E8FC-4B7D-8F8A-874CFCE56309Q28223065-0B3FDE98-2273-48C8-83D4-F4D7659B8C6AQ28547968-8B35440A-5463-4320-BEEF-CE1B0061F443Q30654030-2F674D3F-EFC9-4215-AE4E-B9B40FBE6C99Q33623030-4E458C4A-3FBE-4476-9F09-14F5F7B6761FQ33624190-53336585-9B94-49AF-83B4-6055B2BCAB01Q33900459-832D9DF8-3A1D-4BB3-9375-032FBE47D838Q34058254-1157939D-648C-4EB5-9B18-90B9DBA880C1Q34059119-0E2CF93F-6A4F-48B0-BA09-A4DAE3FAB240Q34059575-9B2FAFB3-DDDB-4F51-8808-7EFEA370FCE1Q34102246-0AE4C3DC-FC4D-4BB3-AF37-6F6D5B1A8A9AQ34280466-EC195E56-5AAE-4300-BF17-C72076795241Q34303589-1782FBFC-3958-4719-9054-E4479237148FQ34303603-F87AF518-85E9-45DC-A445-CD8C161D59E4Q34597650-9EAB3A90-7019-4A88-9EA5-BD624AE57A49Q35105844-0EC57EE3-3E8A-4922-962D-DC1C1195043BQ35169003-9B1EDE29-0B57-497C-8793-043CBB3A2334Q35363594-6BFCEA0E-7C69-4874-BE15-BB9FB10ABDE8Q35607740-6E994069-EAC0-413E-87E3-3685D0555662Q35843260-8171E15B-FD61-4982-91DC-18F9B6B56772Q36076011-077642E8-395F-475A-B07B-F2198E844755Q36172087-E917C598-3D24-457F-B940-D05FC60E253DQ36281109-448426B8-EAB0-4D15-98B6-5C3883A9D048Q36368294-8F8E93C5-CFA4-4F06-ACCD-A99478368B59Q36397384-2B0161AA-3E83-4BB3-9402-902FBDAB48FCQ36603434-406EB2D2-AC9C-4436-B001-F096153931C6Q36969977-908B9095-E7D1-410C-BF61-B201988DF7EEQ37263541-D04B8883-9C35-4076-A324-EEE267605283Q37263786-31CB752D-BC5B-4F7D-80DC-D7FA6C7AA1AAQ37547275-F4266ABE-235B-4FCD-B604-864952A92A19Q37643598-5DA91B96-BE57-4838-A024-BF92D25708C9Q37967710-4CB5FC74-D05A-49B4-9C74-F3B9F5E4946AQ38009758-A5BA0DCB-3D15-41E1-B9EF-923589D383E8Q38060236-C3C0E47E-DDAB-4360-BE3A-AD0E516C0596Q38774333-6E9607B0-D1D1-4E7D-97A0-2E2977CA4D38Q38856111-15ACFAF7-D242-4CD8-BCF0-634651FEC671Q39421000-5EB0B84F-7A32-41B8-A8EF-995DA71BA75CQ39498339-B69B6A27-BEB5-437F-8307-6809B22F643AQ39813922-C13AF62D-32AD-4FFD-8E43-31C2E48E7FBC
P2860
Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Compensation by the E138K muta ...... ed with the M184I/V mutations.
@ast
Compensation by the E138K muta ...... ed with the M184I/V mutations.
@en
type
label
Compensation by the E138K muta ...... ed with the M184I/V mutations.
@ast
Compensation by the E138K muta ...... ed with the M184I/V mutations.
@en
prefLabel
Compensation by the E138K muta ...... ed with the M184I/V mutations.
@ast
Compensation by the E138K muta ...... ed with the M184I/V mutations.
@en
P2093
P2860
P356
P1433
P1476
Compensation by the E138K muta ...... ed with the M184I/V mutations.
@en
P2093
Bluma G Brenner
Eugene L Asahchop
Hong-Tao Xu
Mark A Wainberg
Maureen Oliveira
Peter K Quashie
Yudong Quan
P2860
P304
11300-11308
P356
10.1128/JVI.05584-11
P407
P577
2011-08-17T00:00:00Z